Cadila Healthcare gets EIR for Ahmedabad plant from USFDA
The EIR report is given to an establishment after the completion of an inspection by the USFDA
New Delhi: Drug firm Cadila Healthcare Friday said it has received an Establishment Inspection Report (EIR) from the US health regulator for its manufacturing plant in Ahmedabad.
"The company's Oral Solid Dosage drug manufacturing plant located at SEZ, Ahmedabad has received an Establishment Inspection Report (EIR) from the USFDA following the inspection carried out in January 2016," Cadila Healthcare Ltd said in a BSE filing.
The EIR report is given to an establishment after the completion of an inspection by the USFDA. The company further said:
"The receipt of EIR indicates the successful closure of the inspection points raised. It may be mentioned that this plant is a separate manufacturing unit and does not form a part of the Moraiya formulations manufacturing facility."
Shares of the company were trading at Rs 385.85 on BSE, up 2.77 percent, from previous close.
The top gainers were Power Grid, Bharti Airtel, Asian Paints, Maruti and UltraTech Cement. The top losers were Bajaj Financial Services, Infosys, Tata Consultancy Services, Sun Pharma and Hindustan Unilever
The top gainers of BSE Sensex were SBI, Tata Steel, Maruti, Axis Bank and Tech Mahindra. The top laggards were Infosys, Asian Paints, Hindustan Unilever, Nestle India and Bajaj Finance
All the sectoral indices ended in red amid rise in oil prices. Realty, auto and metal stocks dip in closing trade